A longitudinal uncontrolled study of cerebral gray matter volume in patients receiving natalizumab for multiple sclerosis.

Khalid F, Tauhid S, Chua AS, Healy BC, Stankiewicz JM, Weiner HL, Bakshi R

Int J Neurosci. 2016 May 4:1-24. PMID: 27143245. Abstract